Dermorphin

ID: dermorphin

Aliases: DERMORPHIN, frog-skin opioid peptide

Type: compound

Route/form: no approved human route; opioid peptide research/illicit context

Status: unapproved_research_or_illicit

Evidence level: preclinical

Best data tier: non-human experimental

Support scope: non-human/mechanistic, review/regulatory

Source types: preclinical, review

Linked sources: 2

Broad outcomes: PEDs / AAS / thermogenics, Pain / addiction / acute care, Safety / regulatory

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• mu-opioid receptor agonism
• opioid analgesia pathway

Optimization domains

• pain
• opioid
• doping
• research peptide

Research basis

• Dermorphin and analogs are potent opioid-peptide pharmacology tools.
• Preclinical opioid-receptor work gives a clear mechanism.

Limits, risks, and missing evidence

• No wellness/performance rationale; opioid agonism makes this a high-risk entry.

Risk flags

• opioid
• respiratory depression
• dependence misuse
• controlled substance context
• doping risk

Linked papers, labels, and reviews

1. Opioid peptide-derived analgesics
   review / pubmed_dermorphin_opioid_peptide_review_2005
   Mechanistic opioid peptide context including dermorphin-derived ligands.
2. Peripheral mu-opioid receptor activation by dermorphin analog alleviates behavioral and neurobiological alterations in a mouse model
   preclinical / pubmed_dermorphin_peripheral_mu_2024
   Recent animal-mechanism anchor; not human safety/efficacy evidence.